Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – NETs and endocrine tumours

4991 - Relation between objective tumor shrinkage and progression-free survival (PFS) in the NETTER-1 population

Date

30 Sep 2019

Session

Poster Discussion – NETs and endocrine tumours

Presenters

Marianne Pavel

Citation

Annals of Oncology (2019) 30 (suppl_5): v564-v573. 10.1093/annonc/mdz256

Authors

M.E. Pavel1, P. Broberg2, M. Caplin3, P. Ruszniewski4, J. Strosberg5, P. Santoro2, L. Ravasi6, E. Krenning7

Author affiliations

  • 1 Gastroenterology And Hepatology, Endocrinology & Metabolic Diseases, Universitätsklinik Erlangen, 91054 - Erlangen/DE
  • 2 R&d, Advanced Accelerator Applications, a Novartis company, 1204 - Geneva/CH
  • 3 Neuroendocrine Tumour Unit, Royal Free Hospital School of Medicine, NW3 2QG - London/GB
  • 4 Gastroenterology, Beaujon Hospital APHP, 92110 - Clichy/FR
  • 5 Gi Oncology, H. Lee Moffitt Cancer Center University of South Florida, 33612 - Tampa/US
  • 6 Medical Affairs, Advanced Accelerator Applications, a Novartis company, 1204 - Geneva/CH
  • 7 Nuclear Medicine, Erasmus Medical Center, 3015 - Rotterdam/NL

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4991

Background

NETTER-1 demonstrated that Radioligand Therapy (RLT) with LUTATHERA® significantly prolongs PFS in progressive midgut neuroendocrine tumor patients compared to 60 mg octreotide (Oct). In oncology, treatment efficacy has often been associated with early reduction of tumor size. As RLT differs from traditional treatments, we sought to verify whether objective tumor shrinkage predicts duration of PFS by assessing the relations between changes in lesion size and treatment efficacy, evaluated by PFS among NETTER-1 patients.

Methods

Post-hoc analyses were performed on the NETTER-1 population on local tumor imaging assessments on the full analyses set (n = 231) with data cut-off date on June 30th, 2016. The best response (change from baseline in sum of target lesion diameters) during 3 intervals after treatment onset was used as a covariate in a Cox regression, thus differentiating whether the time corresponds to an event or a censoring. One interval corresponded to 150 days, i.e. a month prior to 4th injection; 180 days matched the 4th injection and the last interval was set to no limit.

Results

For patients treated with Oct, Cox regression showed a HR of 0.914 [95% CI: 0.860 – 0.971], p = 0.0034. This suggests that the risk of disease progression decreases by 9% for each incremental percentage of shrinkage. Among the patients treated with Lu, Cox regression showed a HR of 1.006 [0.982 – 1.03] p = 0.6236, suggesting that LUTATHERA® prolonged PFS even when tumor objective response was undetected during treatment cycles. As a sensitivity, a 180-day-limit and no-limit (i.e. using the best response up to time of censoring/event) were also applied. With the 180-day-limit, HRs were 0.952 [0.904 - 1.003], p = 0.0652 and 1.013 [0.991-1.037], p = 0.2523 for Oct and Lu, respectively; similarly the no-limit, HRs were 0.952 [0.922, 0.982] p = 0.0023 and 1 [0.984, 1.017] p = 0.9713.

Conclusions

Durable response of LUTATHERA® treatment goes beyond objective tumor shrinkage. This study conveys crucial information on the patient’s management with respect to LUTATHERA®: treatment benefit of 4 cycles should not be assessed only by objective tumor shrinkage.

Clinical trial identification

NETTER-1: NCT01578239.

Editorial acknowledgement

Legal entity responsible for the study

Advanced Accelerator Applications.

Funding

Advanced Accelerator Applications.

Disclosure

M.E. Pavel: Advisory / Consultancy: Novartis. P. Broberg: Full / Part-time employment: Advanced Accelerator Applications. M. Caplin: Advisory / Consultancy, Speaker Bureau / Expert testimony: Advanced Accelerator Applications. P. Ruszniewski: Speaker Bureau / Expert testimony: Advanced Accelerator Applications. P. Santoro: Full / Part-time employment: Advanced Accelerator Applications. L. Ravasi: Full / Part-time employment: Advanced Accelerator Applications. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.